| ORIGINAL ARTICLE |
|
| Year : 2013 | Volume
: 8
| Issue : 2 | Page : 109-115 |
|
|
Concomitant chemoradiotherapy with docetaxel and cisplatin followed by consolidation chemotherapy in locally advanced unresectable non-small cell lung cancer
Celalettin Eroglu1, Okan Orhan1, Dilek Unal1, Gamze G Dogu2, Halit Karaca2, Mustafa Dikilitas2, Ahmet Oztürk3, Metin Ozkan2, Bünyamin Kaplan1
1 Department of Radiation Oncology, Erciyes University, School of Medicine, Kayseri, Turkey
2 Department of Medical Oncology, Erciyes University, School of Medicine, Kayseri, Turkey
3 Department of Biostatistics and Medical Informatics, Erciyes University, School of Medicine, Kayseri, Turkey
Correspondence Address:
Celalettin Eroglu
Department of Radiation Oncology, Erciyes University, School of Medicine, M.K. Dedeman Oncology Hospital, 38039 Kayseri
Turkey
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/1817-1737.109824
|
|
|
Objectives: To evaluate treatment results and toxicities in patients who received concomitant chemoradiotherapy (CRT) followed by consolidation with docetaxel and cisplatin in locally advanced unresectable non-small cell lung cancer (NSCLC).
Methods: Ninety three patients were included in this retrospective study. The patients received 66 Gy radiotherapy and weekly 20 mg/m 2 docetaxel and 20 mg/m 2 cisplatin chemotherapy concomitantly. One month later than the end of CRT, consolidation chemotherapy with four cycles of docetaxel 75 mg/m 2 and cisplatin 75 mg/m 2 were administered at each 21 days.
Results: Median age of the patients was 57 (range, 30-74). Following concomitant CRT, 14 patients (15%) showed complete and 50 patients (54%) showed partial response (total response rate was 69%). The median follow-up was 13 months (range: 2-51 months). The median overall survival was 18 months (95% confidential interval [CI]: 13.8-22.1 months); local control was 15 months (95% CI: 9.3-20.6 months); progression-free survival was 9 months (95% CI: 6.5-11.4 months). Esophagitis in eight (9%) patients, neutropenia in seven (8%) patients and pneumonitis in eight (9%) patients developed as grade III-IV toxicity due to concomitant CRT.
Conclusion: Concomitant CRT with docetaxel and cisplatin followed by docetaxel and cisplatin consolidation chemotherapy might be considered as a feasible, and well tolerated treatment modality with high response rates despite the fact that it has not a survival advantage in patients with locally advanced unresectable NSCLC. |
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
